New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2013
06:06 EDTAGNAllergan has 'sleeper hit' with Ozurdex, says BMO Capital
BMO Capital believes Allergan's biodegradable intravitreal implant for the treatment of diabetic macular edema, Ozurdex, will be approved in mid-2014 and be a "sleeper hit" for the company. BMO thinks Ozurdex, which is currently approved for macular edema related to retinal vein occlusion, can be a $200M-$300M product by 2020 in the U.S. alone. The firm raised its price target for Allergan shares to $117 from $112 and keeps an Outperform rating on the stock.
News For AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 21, 2015
12:30 EDTAGNGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use